Literature DB >> 3050524

Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus.

C J Baker1, M A Rench, M S Edwards, R J Carpenter, B M Hays, D L Kasper.   

Abstract

Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus is a promising strategy for the prevention of perinatal infections caused by group B streptococci. To explore the feasibility of this strategy, we vaccinated 40 pregnant women at a mean gestation of 31 weeks with a single 50-microgram dose of the Type III capsular polysaccharide of group B streptococcus. The only adverse effect detected was a mild local reaction in nine women (22 percent). Of the 35 women with low or unprotective antibody levels before immunization (less than 2 micrograms per milliliter), 20 (57 percent) responded to the vaccine. The geometric mean antibody level rose from 1.3 to 7.1 micrograms per milliliter four weeks after vaccination (P less than 0.02), and these levels persisted at delivery and three months post partum. Sixty-two percent of the vaccine-induced immunoglobulin in the mothers was IgG, which readily crosses the placenta. Infant antibody levels in cord serum correlated directly with maternal antibody levels at delivery (r = 0.913, P less than 0.001). Of the 25 infants born to women who responded to the vaccine, 80 percent continued to have protective levels of antibody at one month of age and 64 percent had protective levels at three months. Serum samples from infants with greater than or equal to 2 micrograms of antibody to Type III group B streptococcus per milliliter uniformly promoted efficient opsonization, phagocytosis, and bacterial killing in vitro of Type III strains. This effect could be mediated exclusively by the alternative complement pathway. Although this vaccine with an overall response rate of 63 percent is not optimally immunogenic, we conclude that maternal immunization is feasible and can provide passive immunity against systemic infection with Type III group B streptococcus in the majority of newborns. Larger trials with better vaccines will be required to evaluate the safety and clinical effectiveness of this strategy.

Entities:  

Keywords:  Age Factors; Americas; Antibodies; Antibody Formation; Bacterial And Fungal Diseases; Biology; Delivery Of Health Care; Demographic Factors; Developed Countries; Developing Countries; Diseases; Health; Health Services; Immunity; Immunization; Immunologic Factors; Infant; Infections; Maternal-fetal Exchange; North America; Northern America; Physiology; Population; Population Characteristics; Pregnancy; Primary Health Care; Reproduction; United States; Vaccination; Youth

Mesh:

Substances:

Year:  1988        PMID: 3050524     DOI: 10.1056/NEJM198811033191802

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  64 in total

1.  Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines.

Authors:  H K Guttormsen; A H Sharpe; A K Chandraker; A K Brigtsen; M H Sayegh; D L Kasper
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.

Authors:  C Gravekamp; D L Kasper; L C Paoletti; L C Madoff
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  The prevention of early-onset group B streptococcal infections in the newborn.

Authors: 
Journal:  Can J Infect Dis       Date:  1994-11

4.  Neonatal sepsis and neutrophil insufficiencies.

Authors:  John Nicholas Melvan; Gregory J Bagby; David A Welsh; Steve Nelson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2010-06       Impact factor: 5.311

5.  Antigen-specific immune responses to influenza vaccine in utero.

Authors:  Deepa Rastogi; Chaodong Wang; Xia Mao; Cynthia Lendor; Paul B Rothman; Rachel L Miller
Journal:  J Clin Invest       Date:  2007-06       Impact factor: 14.808

6.  Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.

Authors:  L C Paoletti; M R Wessels; A K Rodewald; A A Shroff; H J Jennings; D L Kasper
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.

Authors:  Hsiao-Hui Yang; Lawrence C Madoff; Hilde-Kari Guttormsen; Yong-Dong Liu; Lawrence C Paoletti
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

8.  Peripartum transmission of penicillin-resistant Streptococcus pneumoniae.

Authors:  L Clifford McDonald; Kris Bryant; James Snyder
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent.

Authors:  R Bhushan; B F Anthony; C E Frasch
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

10.  Murine monoclonal antibodies to type Ib polysaccharide of group B streptococci bind to human milk oligosaccharides.

Authors:  D G Pritchard; B M Gray; M L Egan
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.